Monica Xu

Special Counsel
Full contact info

I am passionate about supporting emerging companies and investors in cross-border transactions with my expertise and practical business judgment.

Passions

Reading

Tennis

Hiking

Dance

Key stats on Monica

800+

private financings completed for clients globally

1st

and afterwards investments in the PRC completed for many fund clients

Founding member of Cooley’s Shanghai office and the longest-serving attorney among Cooley Asia offices

Experience

ProfoundBio Announces $1.8 Billion Acquisition by Genmab

April 3, 2024

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Rowook Park
Partner, San Diego
Ruomu Li
Partner, Shanghai
Jenny Ge
Associate, Santa Monica
Ross Eberly
Partner, Santa Monica
Megan Browdie
Partner, Washington, DC
Christopher Kimball
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Jamie Leigh
Partner, San Francisco
Izzy Lubarsky
Partner, New York
Barbara Mirza
Partner, Santa Monica
Sonia Nath
Partner, Washington, DC
Jean Park
Partner, New York
Stacey A. Bradford
Special Counsel, Washington, DC
Jeff Goldman
Special Counsel, Palo Alto
Amy Hallman Rice
Special Counsel, San Diego
Karen Tsai
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Julia R. Brinton
Special Counsel, Washington, DC
Megan Drill
Associate, San Diego
Mari Dugas
Associate, Washington, DC
Allison Kutner
Associate, New York
Jiqiang Lin
Associate, New York
Tyler Saavedra-Buckley
Associate, San Francisco
Patrick Sharma
Associate, Santa Monica
Ivy Wang
Associate, Shanghai
Monica Xu
Special Counsel, Shanghai
Freddy Yip
Associate, Hong Kong
Zhijing Yu
Associate, Singapore
Andy Zachrich
Associate, San Francisco
Letian Wei
Legal Consultant, Shanghai

Related Practices & Industries

ProfoundBio Announces $112 Million Oversubscribed Series B

February 14, 2024

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its $112 million oversubscribed Series B financing.

Read more

Related contacts

Patrick Loofbourrow
Partner, Singapore
Monica Xu
Special Counsel, Shanghai
Ivy Wang
Associate, Shanghai
Zixiang Liu
Associate, Shanghai
Xander Lee
Partner, Santa Monica
Charlie Kim
Partner, San Diego
Christopher Kimball
Partner, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Sarah Oliai
Associate, Washington, DC
Letian Wei
Legal Consultant, Shanghai

Related Practices & Industries

InxMed Raises $50 Million Series B

March 10, 2022

Cooley advised InxMed on its $50 million Series B financing. Partner Christina Zhang led the team advising InxMed, which is a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors.

CS Capital led the round, with participation from AIHC Fund, Growth Fund and Hosencare Fund, as well as existing investor Ennovation Ventures. InxMed will use the funds to accelerate ongoing clinical trials of IN10018 for multiple cancer types in the US and China, to advance more stroma-targeting pipelines into clinics this year, and to strengthen research and development capabilities in Nanjing, China.

Related contacts

Monica Xu
Special Counsel, Shanghai
Lunga Su
Associate, Shanghai

Related Practices & Industries

EpimAb Biotherapeutics Raises $120 Million Series C

March 23, 2021

Cooley advised EpimAb Biotherapeutics, a clinical-stage biotech company specializing in bispecific antibody development, on its $120 million Series C financing. China Merchants Bank International and Mirae Asset Financial Group co-led the round, which also included participation by Hony Capital, Cormorant Asset Management and other new investors, as well as existing investors such as Decheng Capital, SDIC Fund and Sherpa Healthcare Partners. EpimAb will use the new capital for the ongoing clinical development of three of its clinical assets and to expand its pipeline of novel bispecific antibodies and other biologics. Partner James Lu led the team advising EpimAb on the financing round.

Related contacts

Monica Xu
Special Counsel, Shanghai
Lunga Su
Associate, Shanghai

Related Practices & Industries

DualityBio Announces HK$1.64 Billion IPO

April 24, 2025

Cooley advised the underwriters of Duality Biologics (DualityBio), a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate therapeutics for patients with cancer and autoimmune diseases, in connection with its HK$1.64 billion global initial public offering (IPO).

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Xander Lee
Partner, Santa Monica
Vince Sampson
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Monica Xu
Special Counsel, Shanghai
Hilda Li
Associate, Hong Kong
Zixiang Liu
Associate, Shanghai
Patrick Sharma
Associate, Santa Monica
Yiying Wang
Associate, Shanghai
Yunxiang Xu
Associate, Shanghai
Kaiting Yang
Associate, Hong Kong
Tonny Yu
Associate, Hong Kong
Tonny Yu
Associate, Hong Kong
Letian Wei
Legal Consultant, Shanghai
Cindy Pan
International Legal Project Manager, Hong Kong
Zoe Wang
International Legal Project Manager, Shanghai
Philip Kwan
Senior Legal Assistant, Hong Kong
Jin Wang
Senior Legal Assistant, Beijing

Related Practices & Industries

View more

Admissions and credentials

New York